about
Safe handling of oral antineoplastic medications: focus on targeted therapeutics in the home settingImatinib in chronic myeloid leukemia: an overviewRole of solute carriers in response to anticancer drugsNilotinib counteracts P-glycoprotein-mediated multidrug resistance and synergizes the antitumoral effect of doxorubicin in soft tissue sarcomasATRA-induced cellular differentiation and CD38 expression inhibits acquisition of BCR-ABL mutations for CML acquired resistanceImatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells.RNA interference screen identifies Abl kinase and PDGFR signaling in Chlamydia trachomatis entry.Ponatinib reduces viability, migration, and functionality of human endothelial cells.Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia.Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumorsImatinib plasma trough concentration and its correlation with characteristics and response in Chinese CML patients.Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).Update on the treatment of gastrointestinal stromal tumors (GISTs): role of imatinib.Targeting protein kinases in central nervous system disordersImatinib: a breakthrough of targeted therapy in cancer.Optimizing adherence to adjuvant imatinib in gastrointestinal stromal tumor.Molecular basis and management of gastrointestinal stromal tumorsBiliary excretion of imatinib and its active metabolite CGP74588 during severe hepatic dysfunction.A phase I dose-escalation study of imatinib mesylate (Gleevec/STI571) plus capecitabine (Xeloda) in advanced solid tumorsEfficacy, safety, and pharmacokinetics of imatinib dose escalation to 800 mg/day in patients with advanced gastrointestinal stromal tumors.Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes.The pharmacogenetics of imanitib.Effects of imatinib mesylate on the pharmacokinetics of paracetamol (acetaminophen) in Korean patients with chronic myelogenous leukaemia.Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate.Monitoring response and resistance to treatment in chronic myeloid leukemia.Pharmacokinetics interaction between imatinib and genistein in rats.Dose study of the multikinase inhibitor, LY2457546, in patients with relapsed acute myeloid leukemia to assess safety, pharmacokinetics, and pharmacodynamicsTyrosine kinases inhibition by Imatinib slows progression in chronic anti-thy1 glomerulosclerosis of the ratImatinib as the first and only treatment in Europe for adult patients at significant risk of relapse following gastrointestinal stromal tumor removal.Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancerFlumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants.Geminin overexpression promotes imatinib sensitive breast cancer: a novel treatment approach for aggressive breast cancers, including a subset of triple negativeImatinib mesylate: past successes and future challenges in the treatment of gastrointestinal stromal tumors.Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein.Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial.Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies.Targeted therapies to treat non-AIDS-defining cancers in patients with HIV on HAART therapy: treatment considerations and research outlook.An LC-MS/MS method for rapid and sensitive high-throughput simultaneous determination of various protein kinase inhibitors in human plasma.Imatinib attenuates inflammation and vascular leak in a clinically relevant two-hit model of acute lung injuryDrug-Drug Interaction Potentials of Tyrosine Kinase Inhibitors via Inhibition of UDP-Glucuronosyltransferases.
P2860
Q23923997-B2D8CCD7-B710-460F-8267-918AF680BC9EQ26865086-80572DAF-6274-4E76-9A2B-167FB8840C23Q27027625-783B68F9-B922-4A12-9071-383B659D60AAQ28483929-C4852DD5-4C1D-4DE4-9A0A-5B2E9D87A722Q28540033-1A574175-63E1-497D-BE5C-15D42922E833Q33285468-31A493BE-62B6-47C2-8D6C-4352ADD035A1Q33325917-D866B0C7-6F83-4F1C-AECF-2522663A2EA6Q33364077-8E8AF223-F774-4CE8-B59D-F16BF9003C08Q33394772-2B821BC8-C4AC-441E-B3D8-58AF25FC3272Q33412724-598B7F7E-56E2-42E6-8C0A-2AE4582CEFF1Q33557847-CF7C53BA-359B-4C96-9731-4A440FE49313Q33574578-73AD0F4C-4E62-46E2-96FC-A9C5E1639821Q33644791-208161F8-7B9E-42D2-A587-A547EE1A066AQ33671660-42A5557F-F020-4788-9302-01C8862B71C1Q33747261-BECAAD83-C956-4953-B02F-FB45288DB81BQ33885999-949C9688-995A-473F-AA16-68473BB687E4Q33903598-F2E3F33B-560C-4633-9332-B7960D55B2D2Q33908105-6FC48EBF-AF0A-4768-91EE-C4C0F3C521CEQ33919101-049F134C-0A03-467C-9F03-AEFB9597657EQ34339623-5327B48E-8D91-41B9-B7EC-FB0B93500DD9Q34389029-A71B8779-8025-4958-97C5-B799C50931DBQ34469295-3F9FFEF7-07B7-4D64-98AF-7EDBDB0CDB70Q34580581-671532C3-EA7F-4279-AD9F-05B8ACA040ADQ34596126-FFF0130B-B519-4851-BE3B-DEF45B720B81Q34761663-4356BF11-AA98-4F4A-BE11-B1B9ABF80887Q34986811-E5FC2958-D001-4331-B6AA-6817B75A90D2Q35003666-F9FFBD62-A2EF-4F6B-9F02-AFF8D9F38949Q35015952-0B84BBBE-AB39-4F19-AE3F-2E66ED0697EDQ35026332-CB134E8F-835A-436E-B0CF-D4B8042E8072Q35035596-0276A36D-7A32-404D-805A-00038FCEDF74Q35051746-9285BB97-70C7-4330-979E-0A60EA74D5EBQ35161841-1DB08ED9-19C1-415C-976C-A10771D06654Q35607790-26088B3D-302F-489D-B336-3AA6FF00C0DEQ35827616-011F3CF5-35CE-49B9-9C3B-104993940B3AQ35930616-002BF6BD-2223-4994-BD5C-2DAA7BACF27AQ36002546-AA483E72-77BE-471C-9881-2237D047C043Q36040272-6F18772F-8C85-46CF-9251-38E362B1AC64Q36083906-900C7983-2116-4680-869D-73003E0EE687Q36345868-8617F2FA-4FED-4C1B-AB37-749D4194144EQ36353657-B3CE2875-0A9B-4F9A-9D65-AA6F54CDBC48
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Clinical pharmacokinetics of imatinib.
@ast
Clinical pharmacokinetics of imatinib.
@en
type
label
Clinical pharmacokinetics of imatinib.
@ast
Clinical pharmacokinetics of imatinib.
@en
prefLabel
Clinical pharmacokinetics of imatinib.
@ast
Clinical pharmacokinetics of imatinib.
@en
P2093
P1476
Clinical pharmacokinetics of imatinib.
@en
P2093
Horst Schran
Peter Lloyd
P304
P356
10.2165/00003088-200544090-00001
P577
2005-01-01T00:00:00Z
P6179
1018019066